Powerful perspectives
Industry Insight
Scientific innovation in uveal melanoma
Industry Insight
Opportunities and challenges in oncology immunotherapy
Industry Insight
Reflections from our CEO
Industry Insight
Pancreatic cancer – our commitment to scientific advances
Industry Insight
A bold new era in global cancer drug discovery
Industry Insight
A note from our CEO
Industry Insight
Realising the potential of autotaxin therapy in cancer
Industry Insight
PI3Kδ inhibitors offer serious promise in solid tumors
Industry Insight
Emerging therapies offer hope for uveal melanoma patients
All articles
Press release
iOnctura commences randomized Phase II study in metastatic uveal melanoma
Press release
iOnctura strengthens leadership with appointments of Chief Business Officer and Board Chair
Data & publication
Transforming growth factor beta receptor type I (TGF-βRI) kinase inhibitors IOA-359 and IOA-360 stimulate erythropoiesis in MDS
Press release
iOnctura reaches new clinical milestones in uveal melanoma
Press coverage
Drug Target Review – Biotech leader champions targeted cancer treatments and diversity
Data & publication
High levels of autotaxin and lysophosphatidic acid predict poor outcome in treatment of resectable gastric carcinoma
Data & publication
Roginolisib (IOA-244), a first oral allosteric modulator of phosphoinositide 3-kinase inhibitor delta (PI3Kδ) in patients with metastatic uveal melanoma
Press coverage
MedNous – Small company, big theme: How iOnctura is pursuing drug resistance
Press release
iOnctura announces expansion of roginolisib clinical trial program to NSCLC
Press coverage
Endpoints News – iOnctura raises €80M to advance early-stage rare eye cancer treatment
Press coverage
FirstWord Pharma – With fresh €80M in hand, iOnctura looks to chart new PI3K path
Press release
€80 million Series B financing to progress pipeline through Phase II trials
Looking for media
resources?